This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Impact of asset freeze on patent portfolio a non-issue for US panel

By Melissa Ritti ( May 14, 2025, 19:24 GMT | Insight) -- In oral arguments in a consolidated appeal over an asset freeze sought and secured by the US Securities and Exchange Commission, a US appeals court left unaddressed claims by Reven Holdings, maker of Rejuveinix, that the relief ordered by a Colorado federal judge leaves it unable to maintain its patent portfolio. Last summer, the biotechnology and pharmaceutical company launched a $100 million lawsuit against the federal government in connection with the SEC inquiry, which it says constitutes an impermissible taking under the Fifth Amendment.A bid by Reven Holdings and its founders Brian Denomme, Peter Lange and Michael Volk to lift a freeze on Reven’s assets to resume clinical trials on the cardiovascular and anti-inflammatory drug Rejuveinix, explore licensing opportunities for the same and pay patent maintenance fees seemingly fell flat today....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections